Compare Accenture plc (ACN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs Inovio Pharmaceuticals Inc — how do they compare? Accenture plc trades at $138.89 (market cap $86.98B), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $99.55M). The key difference: Accenture plc is far larger — about 873.7× Inovio Pharmaceuticals Inc's market cap, and Accenture plc pays a 4.59% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ACN | INO | |
|---|---|---|
Market Cap | $86.98B | $99.55M |
Sector | Technology | Health |
52-Week High | $303.33 | $2.87 |
52-Week Low | $124.41 | $1.05 |
Enterprise Value | $85.20B | $70.56M |
Dividend Yield | 4.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
INO trades at $1.21, down 2.02% today, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company shows minimal revenue of $65,340 (2025) with significant losses (-$84.95M net income), though recent earnings beats and FDA review of INO-3107 (PDUFA date October 30, 2026) provide catalysts. Analyst consensus is 53% buy, but multiple class action lawsuits pose legal risks.
Outlook hinges on FDA approval of INO-3107, which could drive upside, but high cash burn (-$21.54M net cash flow in 2025) and negative margins (-130,000% net income margin) underscore substantial operational risks. Investors face a binary event-driven opportunity with elevated volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
